FOXO4-DRI (15mg)
Senolytic Peptide
Researched for clearing senescent cells.
The Science
What is FOXO4-DRI?
FOXO4-DRI (D-Retro-Inverso) is a novel senolytic peptide that selectively targets and eliminates senescent cells—aged, dysfunctional cells that accumulate in tissues and contribute to age-related decline and disease.
This innovative peptide works by disrupting the interaction between FOXO4 and p53 proteins within senescent cells. By interfering with this survival pathway, FOXO4-DRI induces apoptosis specifically in senescent cells while leaving healthy cells unaffected.
Originally developed through groundbreaking research at Erasmus University Medical Center, FOXO4-DRI represents a targeted approach to cellular rejuvenation and has shown remarkable promise in preclinical studies for promoting healthspan and addressing age-related cellular dysfunction.
Laboratory Observations
Key Observed Effects of FOXO4-DRI (15mg)
Cellular Rejuvenation
Targets and eliminates senescent cells that accumulate with age and contribute to tissue dysfunction.
Longevity Support
Research suggests senolytic intervention may support healthspan extension and age-related resilience.
Tissue Health
May support improved tissue function by reducing the senescence-associated secretory phenotype (SASP).
Inflammation Reduction
Senescent cells secrete pro-inflammatory factors; their removal may support balanced inflammatory response.
Metabolic Function
Preclinical data suggests potential benefits for metabolic health markers and cellular energy production.
Recovery Potential
May support improved recovery and adaptation by reducing cellular burden from accumulated senescent cells.
Mechanism of Action
Mechanism of Action
FOXO4-DRI employs a sophisticated molecular approach to selectively eliminate senescent cells through targeted protein disruption.
Cellular Targeting
The peptide specifically identifies and binds to senescent cells through recognition of FOXO4 transcription factors.
Protein Disruption
FOXO4-DRI interrupts the interaction between FOXO4 and p53, destabilizing the survival mechanisms of senescent cells.
Selective Apoptosis
Once the pathway is disrupted, senescent cells undergo programmed cell death while healthy cells remain protected.
FAQ
Frequently Asked Questions
What are senescent cells?+
Senescent cells are aged, dysfunctional cells that have stopped dividing but resist normal cell death. They accumulate with age and secrete inflammatory factors (SASP) that can damage surrounding healthy tissue, contributing to age-related decline and disease.
How does FOXO4-DRI work differently from other senolytics?+
FOXO4-DRI uses a unique mechanism targeting the FOXO4-p53 interaction specifically within senescent cells. Unlike broad-spectrum approaches, this peptide’s D-retro-inverso structure provides enhanced stability and selectivity, minimizing effects on healthy cells.
When will FOXO4-DRI be available?+
Availability updates will be provided when FOXO4-DRI becomes available through the research team. Launch is anticipated within the coming months.
Research-Only Notice
FOXO4-DRI (15mg) is categorized by the FDA as for research-purposes-only. It is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease. The information above summarizes effects observed in laboratory studies to date and is provided strictly for scientific and educational reference.